Sorrento Therapeutics (SRNE)
(Delayed Data from OTC)
$0.01 USD
0.00 (9.09%)
Updated Sep 18, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Sorrento Therapeutics, Inc. [SRNE]
Reports for Purchase
Showing records 1 - 20 ( 186 total )
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
What Does the Scilex Dividend Mean for Sorrento?
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sorrento Declares Stock Dividend of 76M Scilex Shares
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We Spoke too Early, It?s Not Christmas Yet.
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Sorrento Picks Up $125 Million Arbitration Award
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Sorrento Is Considering Potential Dividend of Scilex
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Sorrento Therapeutics completes enrollment of Phase 2 clinical trial of a non-Opioid drug: Resiniferatoxin (RTX) for treatment of knee pain.
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Removing Covid Estimates - Lowering Our Price Target from $16.0 to $5.0
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Term Sheet to Acquire Ancora Medical (Private
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Reports 1Q22 Results - $270M in Cash & Marketable Investments
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: IntraNasal COVISHIELD P1 Study is Enrolled
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Scilex Spinout Edges Closer to Completion; 2021 Financials; Lowering PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Reports 2021 Results; $60M in Revenues & $126M in Cash
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Sorrento Acquires (majority) Ownership in Diagnostic Maker Zhengzhou Fortune Bioscience
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Portfolio Continues to Progress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: COVISHIELD nAb Potentially Neutralizes Omicron
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J